Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
157.24
+9.47 (6.41%)
At close: Jul 17, 2026, 4:00 PM EDT
159.16
+1.92 (1.22%)
After-hours: Jul 17, 2026, 7:52 PM EDT
Palvella Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Palvella Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $229.6. The average 1-year stock price forecast is 46.02% higher than the current stock price, while the lowest is $205 (+30.37%) and the highest is $270 (+71.71%).
Price Target: $229.6 (+46.02%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 15 | 15 | 16 | 15 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates $240 | Buy | Reiterates | $240 | +52.63% | Jul 1, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $227 | Buy | Reiterates | $227 | +44.37% | Jun 25, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $250 | Buy | Reiterates | $250 | +58.99% | Jun 24, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Reiterates $205 | Buy | Reiterates | $205 | +30.37% | Jun 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $255 → $270 | Buy | Maintains | $255 → $270 | +71.71% | Jun 11, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
33.86M
EPS This Year
-5.57
from -3.71
EPS Next Year
-6.82
from -5.57
EPS and Forward PE are based on non-GAAP adjusted numbers.